Ischemic stroke
Conditions
Interventions
Experiment group:Treatment of indobufen + aspirin simulator
Control group:Treatment of aspirin + indobufen simulator
Sponsors
Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Over 50 years old; 2.Non acute lacunar infarction confirmed by imaging (axial section diameter less than 15mm), accompanied by at least one of the following signs on MRI: WMH (Fazekas score >= 2); Enlarged perivascular space (PVS); Intracerebral microbleeds (CMBS); 3.Main complaints: dizziness, or unstable posture, or depression, or cognitive decline.
Exclusion criteria
Exclusion criteria: 1.Stenosis of large intra-and extracranial blood vessels; 2.Patients with cognitive impairment or dementia caused by neurodegenerative diseases; 3.Have a history of acute cerebral infarction, symptomatic non-traumatic intracranial hemorrhage or amyloid cerebrovascular disease; 4.Have a history of coagulation disorder, systemic bleeding, thrombocytopenia or neutropenia; 5.Gastrointestinal bleeding occurred within 6 months before randomization; 6.Major surgery was performed within 30 days before randomization; 7.Severe hepatic and renal insufficiency (severe hepatic insufficiency is defined as ALT value > 3 times the upper limit of normal or AST value > 2 times the upper limit of normal; severe renal insufficiency is defined as creatinine > 2 times the upper limit of normal); 8.Have a history of cardiogenic embolism such as atrial fibrillation and atrial myxoma; 9.Diagnosis or proposed diagnosis of acute coronary syndrome; 10.Other antithrombotic treatments are planned for the study period, Including antiplatelet drug therapy (such as open label aspirin, GPIIb / IIIa inhibitor, clopidogrel, tigrel, prasugrel, dipyridamole, Ozagrel, cilostazol, etc.) and anticoagulant drug therapy (such as warfarin, thrombin and factor Xa inhibitor, bivalirudin, hirudin, argatroban, unfractionated heparin and low molecular weight heparin, etc.); 11.Heparin or oral anticoagulants were used within 10 days before randomization; 12.Have a history of drug or food allergy and are known to be allergic to the drug components of this study; 13.Revascularization (any angioplasty or vascular surgery) is planned within 3 months after randomization; 14.Long term (> 7 days) use of NSAIDs is expected during the study; 15.Severe cardiopulmonary disease, and the researcher thinks it is not suitable to participate in this study; 16.Patients with malignant tumors, or patients whose life expectancy is less than 3 months, or patients who are unable to complete the study for other reasons; 17.Women of childbearing age who have negative pregnancy test but refuse to take effective contraceptive measures; Pregnant or lactating women; 18.Participated in other drug or device trials 30 days before randomization; 19.Unable to understand and / or obey the study procedures and / or follow-up due to mental illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptom;Neuropsychological scale;Imaging data; | — |
Countries
China
Contacts
Public ContactXu Yun
Affiliated Drum Tower Hospital of Nanjing University Medical School
Outcome results
None listed